Small Molecules for Immunology, Oncology & COVID

Cambridge Healthtech Institute’s 2nd Annual

Small Molecules for Immunology, Oncology & COVID

Discovering Oral-Based Therapeutics for Autoimmunity, Cancer and Infectious Diseases

May 19-20, 2021

Small molecule-based drugs, because of their oral bioavailability and ability to reach intracellular targets, are especially well-suited to treat chronic conditions such as autoimmune or inflammation-related diseases. The drug discovery industry’s R&D spotlight is also broadening to small molecule therapeutics for oncology and immuno-oncology now that more intracellular, ‘non-biologics accessible’ targets have been uncovered. Cambridge Healthtech Institute's 2nd Annual Small Molecules for Immunology, Oncology & COVID conference will bring together discovery chemists working in the area of immunology and oncology as well as those whose work has recently shifted to COVID19. Even with encouraging prospects of widespread COVID vaccination in the near future, the industry is recognizing the need for affordable, convenient therapeutics to fight potential future COVID and related viral outbreaks.

 

Coverage will likely include:

 

  • Modulating nuclear hormone receptors (ROR, AhR) or the innate immune system for autoimmunity and cancer 
  • Targeting STING for immunology or oncology
  • Emerging intracellular targets in immuno-oncology or autoimmunity (adenosine, kyneurin, etc.)
  • New non-biologic IO checkpoint inhibitors
  • Remodeling the tumor microenvironment with small molecules
  • COVID moonshot examples and other small molecule anti-COVID progress

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is December 18, 2020.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

We hope you can join us for this and the three concurrent day-and-a-half conferences during the second half of our 16th Annual Drug Discovery Chemistry event. Joining this virtual community in real-time allows you to ask questions of the speakers and engage with colleagues. Plus, you can return later to view the concurrent presentations and Q&A panels that you missed, via On-Demand access. 

 

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-628

Email: reymael@healthtech.com